Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion — Update

By Colin Kellaher

 

Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for an initial $2.2 billion, and has struck a deal with asset manager Blackstone to fund development of Ollin's lead asset.

J&J on Monday said the Ollin deal, which includes more than $1.12 billion in potential regulatory and commercial milestone payments, adds OLN324, an investigational bispecific antibody for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.

The New Brunswick, N.J., pharmaceutical giant said Blackstone's private investment platform Blackstone Life Sciences will pay $750 million over multiple years to fully fund the Phase 3 development of OLN324 in exchange for regulatory and sales milestone payments, along with single-digit royalties on sales.

J&J said the Ollin deal, slated to close by the end of the year, expands its ophthalmology business, which offers products spanning surgical vision, contact lenses and ocular surface care

Blackstone Life Sciences, which has $18 billion in assets under management and invests across the life cycle of companies and products within key life-science sectors, in February inked an agreement with J&J to help fund the development of its bleximenib drug candidate for the blood cancer acute myeloid leukemia.

Investment firm Arch Venture Partners, which has racked up billions in profits from early stakes in companies developing methods to detect and treat cancer and other diseases, incubated Ollin, which launched last year with an initial $100 million in financing led by Arch, Mubadala Capital and Monograph Capital.

Ollin in June raised $330 million in a Series B financing round which was co-led by Arch and new investor TCGX.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 16, 2026 10:15 ET (15:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center